Abstract: The disclosure describes compounds of Formula Ia, which in non-limiting aspects contain an asialoglycoprotein receptor (ASGPR) binding moiety and an anti-?1AR binding moiety. Compounds of Formula Ia are useful in preventing, treating, and/or ameliorating heart failure in a subject when administered in therapeutically effective amounts.

Abstract: Core-shell particles and methods of making and using thereof are described herein. The core is formed of or contains one or more hydrophobic materials or more hydrophobic materials. The shell is formed of or contains hyperbranched polyglycerol (HPG). The HPG coating can be modified to adjust the properties of the particles. Unmodified HPG coatings impart stealth properties to the particles which resist non-specific protein absorption and increase circulation in the blood. The hydroxyl groups on the HPG coating can be chemically modified to form functional groups that react with functional groups and adhere the particles to tissue, cells, or extracellular materials, such as proteins.

Abstract: The present invention relates to compositions and methods for binding and detecting or measuring renalase. In one embodiment, the renalase binding molecule measures renalase amount or activity. Thus, in diseases and conditions where a measurement of renalase is beneficial, such renalase binding molecules may act as diagnostics.

Abstract: Systems and methods for performing fault tolerant quantum operations for the 4-legged cat code are provided. The quantum systems include an ancilla qubit dispersively coupled to a first logical qubit. and the quantum system may be operated at least in part by: generating and applying a first drive waveform to the ancilla qubit. the first drive waveform comprising a first comb of 7t-pulses having selective frequencies corresponding to a first selection of even and odd cavity resonance frequencies of the first logical qubit: and reading out a state of the ancilla qubit.

Abstract: The present invention relates to compositions and methods for binding and inhibiting renalase. In one embodiment, the renalase binding molecule inhibits renalase activity. Thus, in diseases and conditions where a reduction of renalase activity is beneficial, such inhibitory renalase binding molecules may act as therapeutics.

Abstract: Quantum systems and techniques are described to generate fault tolerant cluster states for use in quantum computation, quantum networking, and other applications. The systems and techniques include initializing states in first qubits and generating initial resource states by performing first Pauli product measurements on sets of X-type and/or Z-type qubits of the first qubits, the initial resource states comprising qubit cluster states comprising at least three qubits. The final cluster state may then be generated by fusing two or more initial resource states, the fusing comprising performing second Pauli product measurements between qubits of two or more of the initial resource states.

Abstract: Described herein are methods and compositions useful to reduce (partially/inhibit or completely—prevent) skin cancer development in an individual in need thereof.

Abstract: The invention provides a novel filtration apparatus for the selective separation of metals from a mixture thereof. The invention also provides a method for the separation and isolation of metals from a sample using electrochemical precipitation.

Abstract: The present invention relates in part to compositions and methods for treating a wound, or location of interest, in mammal by administering a decellularized extracellular matrix (ECM) lacking thrombospondin-2 (TSP-2-null ECM). In certain embodiments, the invention provides an acellular composition comprising a decellularized TSP-2-null ECM. In certain embodiments, the invention provides a tunable hydrogel comprising a decellularized TSP-2-null ECM. The invention also provides, in certain embodiments, methods for accelerating cellular migration, methods for enhancing cellular invasion, methods for enhancing vascular growth and maturation of a region to be treated, and/or methods for enhancing a wound repair in a mammal in need thereof.

Abstract: In various aspects and embodiments the invention provides a method of treating epilepsy in a subject in need thereof, the method comprising providing to the subject an effective amount of an FLNA modulator. In various embodiments, the FLNA modulator is PTI-125 or kartogenin. In various embodiments, the epilepsy is epilepsy associated with focal cortical dysplasia (FCD) type II or tuberous sclerosis complex (TSC).

Abstract: One aspect of the invention provides a telescope including: at least one lens or mirror arranged to receive collimated light defining an optical axis at a first end and form an image at a last end; and a narrowband interference filter positioned along the optical axis prior to the first end. The narrowband interference filter is tiltably mounted with respect to the optical axis. Another aspect of the invention provides an imager including: an optical collimator; a plurality of lenses or mirrors arranged relative to the optical collimator to receive collimated light from the optical collimator defining an optical axis at a first end and form an image at a second end; and a narrowband interference filter positioned along the optical axis between the optical collimator and the first end. The narrowband interference filter is tiltably mounted with respect to the optical axis.

Abstract: The present invention provides compositions, systems and methods for treating diabetes in a subject. The composition of the present invention includes a decellularized vascular graft, a biocompatible hydrogel encasement with tunable rigidity, and a plurality of cells such as pancreatic islet cells.

Abstract: Methods for increasing the patency of biodegradable, synthetic vascular grafts are provided. The methods include administering one or more cytokines and/or chemokines that promote outward tissue remodeling of the vascular grafts and vascular neotissue formation. The disclosed methods do not require cell seeding of the vascular grafts, thus avoiding many problems associated with cell seeding. Biodegradable, polymeric vascular grafts which provide controlled release of cytokines and/or chemokines at the site of vascular graft implantation are also provided.

Abstract: The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

Abstract: The present invention provides cationic polymeric nanoparticles, and nanoparticle formulations thereof. The invention also provides methods for preparing cationic polymeric nanoparticles, and methods of treating diseases, reducing tumor growth, and increasing uptake of a therapeutic agent by a tumor cell in a subject in need thereof.

Abstract: Provided herein are compositions and methods for high resolution spatial transcriptomic and epigenomic co-profiling of a biological sample.

Abstract: Techniques are described for implementing a class of multimode bosonic codes that protect against errors within an ancilla qubit coupled to a bosonic system, that can be realized experimentally. A logical qubit state is represented by the states of multiple different modes of one or more bosonic systems, which may include multiple modes of a single bosonic system and/or single modes from multiple bosonic systems. Techniques for correcting errors are also described. In particular, a series of operations are described that autonomously detect and correct errors by repeatedly performing a sequence of operations that are each applied to the multiple bosonic modes and/or to the ancilla qubit that is coupled to each of the bosonic modes. The codes allow ancilla errors to propagate to the modes of the bosonic system as correctable errors, where they can be corrected, instead of presenting as logical errors in the ancilla qubit.

Abstract: The present invention includes DNP derivatives that are useful for preventing or treating a metabolic disease or disorder in a subject in need thereof. In certain embodiments, the subject is further administered at least one additional therapeutic agent.

Abstract: Provided herein, in one aspect, is a method of preventing or delaying the onset of clinical type 1 diabetes (T1D), comprising: providing a non-diabetic subject who is at risk for T1D; administering a prophylactically effective amount of an anti-CD3 antibody to the non-diabetic subject; and determining, prior to or after the administering step, that the non-diabetic subject has more than about 5% to more than about 10% TIGIT+KLRG1+CD8+ T-cells in all CD3+ T-cells, which is indicative of successful prevention or delay of the onset of clinical T1D.

Abstract: A platform technology provides particle and nucleic acid conjugates, and compositions thereof, with enhanced targeting to cells, tissues, organs. The particles and nucleic acids and other deliverables contain a synthetic binding protein such as a polypeptide monobody covalently conjugated to the surface of the particle or the nucleic acid, for linking a targeting agent to the particle's surface or the nucleic acid. The particles and nucleic acids and other deliverables optionally contain an antibody non-covalently conjugated to the binding protein, via an Fc domain of the antibody. The particles can include therapeutic agents, diagnostic agents, prophylactic agents, or a combination thereof, to be delivered to desired cells, tissues, and/or organs. The particles and nucleic acids and other deliverables can be used in a wide array of applications including, but not limited to, ex vivo perfusion of mammalian organs and in vivo disease treatment.